Lilly, Cipla to Launch Tirzepatide in India as Yurpeak

Eli Lilly and Cipla have signed a strategic cooperative agreement to distribute and promote tirzepatide in India. Cipla will create a new brand, Yurpeak, to expand access to the drug in areas beyond cities where Lilly is already present.

As part of the agreement, Lilly will remain responsible for the drug's manufacture and supply, while Cipla will handle its distribution and promotion in urban and semi-urban markets.

The price for Yurpeak will be the same as that for Mounjaro, Lilly’s existing brand, which was launched in India in March 2025. After the recent GST reduction in September 2025, the monthly cost varies from Rs 13,124 to Rs 16,404 depending on the dosage and the delivery mode, which can be a vial or multi-dose prefilled KwikPen.

Healthcare professionals will be able to select from six dose strengths available in Yurpeak to provide personalized treatment for adults with type 2 diabetes or obesity, or those who are overweight and have at least one weight-related comorbidity.

“This partnership is a step further towards Lilly's pledge to increase patients' access to innovative healthcare solutions for chronic illnesses," said Winselow Tucker, President and GM, Lilly India.

Also Read: Glenmark Pharma to Launch Ropivacaine Injection in US

Achin Gupta, Cipla’s Global COO, added, "Yurpeak enables us to extend our care for the obesity segment with not only the same volume but also the same commitment that characterizes our work in the respiratory and chronic therapies sectors.”

Tirzepatide is the first dual GIP and GLP-1 receptor agonist to be used as an adjunct to diet and exercise. India, which is home to more than 101 million people with diabetes and nearly 100 million with obesity, is the market where Yurpeak was launched.